In this pilot study, sequential ultrasonic scanning was used to assess (a) whether furosemide injection normally causes an enlargement of kidney size, and (b) whether this effect is blunted in renovascular hypertensives to such a degree as to bear potential diagnostic value. Furosemide caused similar degrees of maximal area enlargement in both kidneys of 10 healthy subjects (16.1 ± 3.9%) and 10 essential hypertensives (14.8 ± 4.2%) whereas in 11 renovascular patients maximal distension of the affected kidneys was significantly blunted (9.4 ± 3.7%) in comparison with that of contralateral kidneys (19.6 ± 7.7%). In the 6 hypertensives with one small kidney not due to renal artery stenosis, maximal enlargement of the affected kidneys averaged 22.8 ± 5.1%, and that of contralateral kidneys 15.8 ± 4.2%. In 8 out of the 11 patients with renovascular hypertension the difference in response between the paired kidneys had values outside the ranges of patients with both the other forms of arterial hypertension. The data suggest that the furosemide test may be of value in the screening for renovascular hypertension.

Keywords:
Renovascular hypertension, Ultrasound, Furosemide, Hypertension
This content is only available via PDF.
© 1982 S. Karger AG, Basel
1982
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.